Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of AVXS-101 in SMA
NCT04042025Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- Dec 2035
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 9
01
Overview
A Phase 3 trial of onasemnogene abeparvovec in spinal muscular atrophy (SMA), sponsored by Novartis. Started Feb 2020; status: active, not recruiting.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT04042025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042025.